Renal artery stenosis (RAS) is increasingly diagnosed in the expanding elderly population and has been implicated in the pathogenesis of renovascular hypertension and chronic kidney disease. 1 The prevalence of RAS is estimated to be between 2% (unselected hypertensives) and 40% (older patients with other atherosclerotic comorbidities). 2 Most cases of RAS are caused by atherosclerosis; other causes, including fibromuscular dysplasia, vasculitis, thromboembolism, and aneurysms, are less frequent. 2 Renal artery stenosis is also diagnosed in patients with peripheral artery disease. Impaired renal function in these patients negatively affects survival, limb salvage, and graft patency rates when they undergo lower extremity revascularization procedures. 3 The pathogenesis of renovascular hypertension is mainly due to the overactivation of the renin-angiotensin-aldosterone (RAA) system by the ischemic kidney. Several studies demonstrated that RAS is strongly associated with cardiovascular morbidity and mortality and may impact the pathogenesis and control of heart failure. 4,5 Therefore, the benefit of RAS intervention should not only include improved control of hypertension and preservation of renal function 6 but also a reduction in the overall inherent cardiovascular risk. 7 During the past 2 decades, renal stenting has proved to be a safe and durable modality for treating RAS with favorable short-and long-term patency. This has led to progressive extension of the indications for this type of intervention. 8 Meanwhile, concurrent with improvements in stent technology, medical management of hypertension improved and challenged the need for an aggressive approach to RAS. Therefore, whether renal artery revascularization affects the outcome in patients with hypertension or renal insufficiency remains ill defined.
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Several cohort studies, 9 systematic reviews, 10 and randomized controlled trials 11 showed no substantial benefit of renal artery angioplasty with respect to hypertension when compared with pharmacotherapy [12] [13] [14] [15] Little or no change in either blood pressure (BP) control or medication requirements has been reported in 30% (range: 0%-54%) of the treated patients. 16, 17 This lack of benefit could be related to the fact that most patients with RAS may have essential hypertension complicated by a renovascular disease. It is also possible that a late chronic stage of RAS hypertension is no longer directly dependent on the RAA system but on local vasoconstrictor and proliferative effects in the arterial wall leading to renal artery revascularization inefficacy. 18, 19 Moreover, it is often difficult to determine to what degree the RAS is responsible for the high BP. Most agree that narrowing the luminal diameter by 70% is almost certainly of hemodynamic significance. The physiologic significance of lesser degrees of stenosis, however, may depend on the resistance of the peripheral renal vasculature or the condition of the renal autoregulatory system. 20 In current practice, angiotensin II receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs) are included in antihypertensive therapy. 21 Yet, in bilateral disease or stenosis of a single kidney, caution is recommended with ACEIs, as renal function can be compromised due to dilatory drug effect on the efferent arterioles. This can reduce the capillary pressure within the glomerulus to below the critical perfusion pressure, and acute renal failure can occur 1 to 14 days after the initiation of treatment with ACEIs. Angiotensin II receptor blockers have effects that are similar to ACEIs. They block the binding of angiotensin II on blood vessels. The normal compensatory increase in filtration rate in surviving nephrons is angiotensin II dependent and therefore abolished by ARBs as well as by ACEIs. It is probable that the renal effects of ACEIs and ARBs in the presence of untreated RAS are close enough to allow them to be considered identical. Furthermore, adverse effects such as hyperkalemia and hypotension are shared by both ACEIs and ARBs and may contribute to the worsening of renal function in the presence of untreated RAS. 22 Therefore, RAS revascularization may extend medical options for hypertension. 7, 23 Although optimal medical therapy usually controls hypertension, progression of the underlying RAS and renal failure frequently occurs, despite antihypertensive therapy. 24 An important RAS may result in renal failure within 5 years after diagnosis. 20 It has been suggested that renal artery stenting should be aimed to prevent renal function decline and delay the requirement for hemodialysis in patients either with unilateral or bilateral disease.
The 2 most recent trials, the Angioplasty and Stenting for Renal Artery Lesions (ASTRAL) 25 and the Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) 26 trials, suggested that renal artery stenting did not confer a significant benefit in patients with atherosclerotic RAS and hypertension or chronic kidney disease when compared to multifactorial medical therapy. Yet, these results should be interpreted critically.
A major concern is that in both studies the effects of renal artery stenting were evaluated in a heterogeneous subset of patients with hypertension or chronic kidney disease who may have a very different risk of cardiovascular and renal adverse events. Another issue is the diagnostic modalities used to identify RAS. The ASTRAL also enrolled patients without hemodynamically significant RAS since 41% of patients eligible had >60% atherosclerosis stenosis that was not confirmed by a central laboratory. Furthermore, this study included those patients who were uncertain to benefit from renal stenting or medical therapy. So, the ASTRAL trial provided evidence that renal artery revascularization is not effective in unselected patients with respect to pharmacotherapy and raised more questions than answers. 27 The data from the CORAL trial also raise some concerns. One major flaw was selection of the RAS to be included in the study. Diagnosis of RAS was made by very different diagnostic modalities and nonstandardized diagnostic criteria (duplex sonography, magnetic resonance angiography, or computed tomography). No attempt was made to univocally confirm the degree of RAS using the same investigation and univocally accepted criteria. A significant percentage of no hemodynamically significant stenosis was also included. In addition, the functional significance of RAS was not evaluated according to renal resistance indices and/or a pressure gradient between distal renal artery and the aorta was not recorded to assess renal autoregulation efficiency. It is widely proved that the renal resistive index (RI) is an accepted marker of vascular interstitial damage to the kidneys, constituting a predictive factor for delayed effects of invasive treatment of RAS. 28 It is widely accepted that a value of RI <0.80 expresses preserved renal autoregulation. Similarly, a pressure gradient between distal renal artery and the aorta <0.90 results in exponential renin release, indicating the potential improvement in renal function after renal artery revascularization RAS. 29 Therefore, these indicators of the potential reversibility of the renal ischemic injury should be considered to select those patients who can actually benefit from renal artery stenting.
None of these functional parameters have been considered to select patients in the CORAL trial. From the analysis of its data, CORAL seems only to suggest that renal artery stenting is not better than medical therapy alone in patients with RAS not always associated with significant renal hypoperfusion.
To conclude, even if the most recent clinical trials have emphasized that medical management should be preferred over stenting to treat RAS, many doubts exist about the optimal management strategy. Certainly, the high cost of endovascular procedures requires a reevaluation of its indications in the present economic environment. A better understanding of RAS consequences on systemic hypertension and on kidney function will allow improving the selection of patients undergoing new medical therapies or interventional approach.
